Dark Forest Capital Management LP Acquires 35,562 Shares of Verve Therapeutics, Inc. (NASDAQ:VERV)

Dark Forest Capital Management LP boosted its holdings in Verve Therapeutics, Inc. (NASDAQ:VERV) by 301.4% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 47,361 shares of the company’s stock after buying an additional 35,562 shares during the period. Dark Forest Capital Management LP owned approximately 0.06% of Verve Therapeutics worth $231,000 as of its most recent SEC filing.

A number of other large investors also recently modified their holdings of VERV. Vanguard Group Inc. increased its position in Verve Therapeutics by 15.7% during the first quarter. Vanguard Group Inc. now owns 6,331,312 shares of the company’s stock worth $84,080,000 after acquiring an additional 859,382 shares during the period. Cubist Systematic Strategies LLC increased its holdings in shares of Verve Therapeutics by 245.5% during the 2nd quarter. Cubist Systematic Strategies LLC now owns 395,699 shares of the company’s stock worth $1,931,000 after purchasing an additional 281,173 shares during the period. Renaissance Technologies LLC lifted its stake in shares of Verve Therapeutics by 138.1% in the second quarter. Renaissance Technologies LLC now owns 474,500 shares of the company’s stock valued at $2,316,000 after buying an additional 275,173 shares during the period. Los Angeles Capital Management LLC acquired a new stake in Verve Therapeutics during the second quarter worth about $1,183,000. Finally, Nikko Asset Management Americas Inc. increased its stake in Verve Therapeutics by 8.1% during the first quarter. Nikko Asset Management Americas Inc. now owns 2,592,198 shares of the company’s stock valued at $34,347,000 after acquiring an additional 194,594 shares during the period. 97.11% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of analysts have recently issued reports on the company. HC Wainwright restated a “buy” rating and set a $15.00 price objective on shares of Verve Therapeutics in a research report on Monday, August 12th. Royal Bank of Canada reduced their price objective on shares of Verve Therapeutics from $25.00 to $20.00 and set an “outperform” rating for the company in a report on Friday, August 9th. Finally, Canaccord Genuity Group lowered their target price on shares of Verve Therapeutics from $30.00 to $29.00 and set a “buy” rating on the stock in a research note on Monday, August 12th. Five investment analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock presently has a consensus rating of “Buy” and an average target price of $26.00.

Verve Therapeutics Stock Performance

Shares of NASDAQ:VERV opened at $4.98 on Monday. The company’s fifty day moving average is $5.72 and its 200-day moving average is $6.65. Verve Therapeutics, Inc. has a 52 week low of $4.30 and a 52 week high of $20.12. The company has a market capitalization of $418.15 million, a PE ratio of -1.74 and a beta of 1.83.

Verve Therapeutics (NASDAQ:VERV) last issued its quarterly earnings data on Thursday, August 8th. The company reported ($0.59) earnings per share for the quarter, topping the consensus estimate of ($0.68) by $0.09. Verve Therapeutics had a negative net margin of 933.08% and a negative return on equity of 35.20%. The firm had revenue of $6.70 million for the quarter, compared to analysts’ expectations of $2.40 million. During the same period in the prior year, the firm earned ($0.87) earnings per share. The company’s quarterly revenue was up 219.0% compared to the same quarter last year. On average, analysts forecast that Verve Therapeutics, Inc. will post -2.65 EPS for the current year.

Verve Therapeutics Profile

Verve Therapeutics, Inc, a clinical stage genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases in the United States. The company's lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver; and VERVE-102, a product candidate that targets the PCSK9 gene for the treatment of HeFH.